Merck Gains Early-Stage Protease Inhibitor For HIV/AIDS Through Ambrilia Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Licensing agreement includes rights to Ambrilia's lead compound PPL-100 in Phase I development as a once-daily, first-line oral therapy for HIV.
You may also be interested in...
Ambrilia To Announce U.S. Octreotide Partner By Year-End
The Canadian company will pair with Teva in Europe on its formulation of Novartis’ acromegaly therapy Sandostatin LAR.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.